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Summary: Although overall self-reported neurocognitive impairment (srni) is 
decreasing in the Swiss HIV Cohort Study, there is a group of patients with persisting 
srni over time, characterized by more past opportunistic infections of the CNS, imperfect 
adherence to ART and depression. 
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Abstract 
 
Introduction 
 Self-reported neurocognitive impairment (srni) in people living with human 
immunodeficiency virus-1 (HIV-1) infection are frequent. We use longitudinal information on 
srni in the Swiss HIV Cohort Study (SHCS) to identify and characterize groups of patients with 
persisting srni over time. 
 
Methods 
We included all SHCS patients who were assessed for srni during at least 5 visits 
spanning at least 2.5 years in 2013-2017. We first compared patients with srni to those without 
srni over the whole study period. Second, we used a hierarchical cluster algorithm to identify 
groups of patients with similar changes of srni over time. In both analyses, we studied clinical 
and demographic factors potentially influencing srni. 
 
Results 
In total, 79’683 questionnaires of 11’029 patients contained information about srni, and 
8’545/11’029 (77.5%) patients had longitudinal information. The overall percentage of patients 
with srni decreased from 19.6% in 2013 to 10.7% in 2017. Compared to patients in the cluster 
with low-level srni over time, patients in the cluster with high-level persisting srni had more 
often a prior opportunistic infection of the central nervous system (CNS) (OR=3.7, p<0.001), 
imperfect adherence to antiretroviral treatment (ART) (OR=2.8, p<0.001) and a depression 
(OR=1.9, p<0.001). 
 
Conclusions 
 Although overall srni is decreasing in the SHCS, there is a group of patients with 
persisting srni over time. Past opportunistic infections of the CNS, imperfect adherence to ART 
as well as depression were associated most with persisting srni. Patients with these 
characteristics should be preferentially tested for neurocognitive impairment. 
 
Keywords: HIV, self-reported neurocognitive impairment 
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Introduction 
Neurocognitive diseases are well-recognized comorbidities in people living with human 
immunodeficiency virus-1 (HIV-1) (PLWH) (1). In 1983, the first case of acquired immune 
deficiency syndrome (AIDS)-related encephalitis was documented and soon after, the AIDS 
dementia complex was defined (2,3). In 1990, a trial started studying AIDS dementia, the first of 
a multitude of trials studying neuro-AIDS (4,5). Until today, HIV-associated neurocognitive 
disorders (HAND), the collective term for neurocognitive diseases in PLWH, is the most common 
form of neurocognitive impairment before the age of 50 worldwide (1). HAND is divided into 
three subgroups: asymptomatic neurocognitive impairment (ANI), mild neurocognitive 
impairment (MND) and HIV-associated dementia (HAD), the most severe form. The prevalence 
of HAND in PLWH in the era of combination antiretroviral therapy (ART) is estimated to be up to 
50%, similar to the prevalence in the pre-ART era, however with a shift from HAD to ANI and 
MND (6,7). Although people suffering from ANI do not show symptoms (measured on a daily life 
activity scale), there are higher chances of developing symptomatic forms of HAND as compared 
to people without ANI (8). In addition, HAND is associated with a decrease in HIV treatment 
adherence (9).   
Our study aims to analyze self-reported neurocognitive impairment (srni) in the Swiss 
HIV Cohort Study (SHCS), which has been shown to correlate with symptomatic forms of HAND 
in a sub study (10). The SHCS with its longitudinal data collection and routine questionnaire 
about srni for all participants provides an ideal framework to study srni on a broad patient 
population. Using longitudinal information about srni, we apply an unsupervised machine 
learning technique tailored to the data at hand with the aim at identifying subgroups of patients 
with similar changes of srni over time. We study potential factors known to influence 
neurocognitive performance such as age, depression, alcohol consumption, recreational drug 
use and ART adherence.   
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Methods 
Swiss HIV Cohort Study 
 The SHCS, launched in 1988, is a prospective multi-center cohort study enrolling adult 
PLWH in Switzerland (www.shcs.ch) (11). It represents at least 50% of all HIV-1 infected 
patients ever diagnosed in Switzerland, 72% of all AIDS cases and 75% of all patients receiving 
ART in Switzerland. For all participants, demographical information is collected at baseline. In 
semiannual follow-up visits, the SHCS collects laboratory and clinical data, including since 2013 
three questions about srni.  
 
Definitions 
 The three questions on srni are: “Is the patient aware of frequent memory loss in normal 
daily life?” (short: frequent memory loss), “Does the patient experience difficulties in paying 
attention in normal daily life?” (short: concentration difficulties) and “Is the patient aware of 
slowing down in reasoning or solving problems?” (short: slowing down in reasoning). Each 
question can be answered with “never”, “hardly ever” and “yes, definitely”. We considered “yes, 
definitely” in at least one of these questions as srni. Opportunistic infections included all stage B 
and C diseases as classified by the Center for Disease Control. Opportunistic infections of the CNS 
included HIV-related encephalopathy, toxoplasmosis of the brain, progressive multifocal 
leukoencephalopathy, cryptococcal meningitis, primary lymphoma of the brain and other forms 
of encephalitis (Section S1.6, Figure S5). The body mass index (BMI) was defined as the weight 
(in kg) divided by the height (in m) squared. Hepatitis C virus (HCV) infection was defined as the 
presence of HCV specific antibodies or a positive HCV RNA test. Syphilis infection was defined as 
a positive venereal disease research laboratory or rapid plasma reagin test confirmed by a 
treponema specific test, where we differentiated whether the patient ever had a positive syphilis 
test result, or whether the first test reported in the SHCS was positive (short: past syphilis). 
Depression was defined as being diagnosed by a psychiatrist or other physician in at least one 
follow-up visit during the study period (12). Imperfect adherence to ART was based on self-
reporting of the patients and defined as missing at least one dose of ART at least once a week. 
Self-reported adherence was validated in Glass et al (13) and shown to be significantly 
correlated with treatment failure and mortality. High alcohol consumption was defined as 
moderate or severe alcohol use, as defined by the WHO guidelines. Intake of recreational drug 
use was based on patients’ self-reporting.  
 
Study Population 
We included patients who completed at least 5 questionnaires on srni spanning at least 
2.5 years in 2013-2017, i.e., information for at least half of the possible observation period 2013-
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2017 with completed questionnaires every six months (Figure 1). First, we compared patients 
with srni in at least one follow-up visit with those patients who did not have srni in all follow-up 
visits. Second, we used a hierarchical cluster approach restricted to patients with srni in at least 
one follow-up visit to identify groups of patients with similar changes of srni over time. 
 
Comparison of patients with and without srni  
We compared patients with srni in at least one follow-up visit to patients having no srni 
in any follow-up visit using Wilcoxon-rank and Fisher exact tests. All analyses were performed 
with R (version 3.4.4).   
 
Definition of clusters 
For each completed questionnaire on srni, the patient could either get a score of ‘0’ if 
there was no srni, ‘1’ for srni in one question, ‘2’ for srni in two questions or ‘3’ for srni in all 
three questions. Figure 2 shows a schematic summary of the algorithm used to find clusters of 
patients with similar scores over time: First, the scores of each patient were linearly 
interpolated over time (Figure 2A).  The area under the curve (AUC) was then calculated for 
each patient in each of the years 2013-2017 separately (Figure 2B). The pairwise distances 
between the AUCs of the patients were calculated using the Manhattan-metric (Figure 2C). 
Based on the pairwise distances, we continued with the complete-linkage clustering algorithm, a 
hierarchical algorithm that sequentially combines initially single elements to clusters. The 
algorithm groups patients with similar trends of srni, measured by the before calculated AUCs 
(Figure 2D). We concentrated on the top three cluster groups of the resulting dendrogram. 
 
Comparison of the clusters 
We compared patients in the largest cluster group with patients in the two other cluster 
groups, respectively. Potential factors associated with srni were compared between the cluster 
groups using univariable and multivariable logistic regression. Continuous covariables were 
included in the form of restricted cubic splines (14), using the R package rms (15) (Section S1.1-
S1.5, Figures S1-S4). 
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Results 
Srni in the SHCS 
In 2013-2017, a total of 83’144 follow-up visits of 11’068 patients were recorded in the 
SHCS. Of those, 79’683 (95.8%) questionnaires of 11’029 (99.6%) patients contained completed 
information about the three questions on srni. The percentage of patients with srni decreased 
over time from 19.6% (1’730/8’812) in 2013 to 10.7% (1’006/9’377) in 2017. The domain with 
most srni was frequent memory loss, followed by concentration problems and slowing down in 
reasoning (Figure 3). A total of 8’545/11’029 (77.5%) patients completed at least 5 
questionnaires spanning at least 2.5 years in 2013-2017, with 2’754/8’545 (32.2%) patients 
having srni in at least one domain (see Section S4, Figures S21, S22 for a comparison of 
patients with longitudinal information about srni and those without).  
 
Comparison of patients with and without srni 
 We compared the key available demographic and clinical characteristics between 2’754 
patients with srni and 5’791 patients without srni (Table 1). Patients with srni were on average 
one year older (p < 0.001), less likely to be male (69.4% vs. 72.6%), p = 0.002) and more likely to 
belong to the transmission group of intravenous drug users (IDU) (17.5% vs. 8.8%, p < 0.001). 
Patients with srni had more often viral blips (35.5% vs. 31.7%, p < 0.001), more often prior 
opportunistic infections (50.3% vs. 43.1%, p <0.001) as well as CNS opportunistic infections 
(6.1% vs. 3.3%, p < 0.001). In addition, patients with srni were more likely to have a current or 
past HCV coinfection (24.1% vs. 15.2%, p < 0.001), a depression (45.8% vs. 22.7%, p < 0.001) 
and imperfect adherence to ART (15.6% vs. 9.5%, p < 0.001). The average time on ART was 2 
years longer for patients with srni (p < 0.001) compared to patients without srni and there were 
differences in ART drug classes: In particular, 78.2% of the patients with srni and 68.7% of the 
patients without srni used protease inhibitors (PI) (p < 0.001) and similarly for integrase strand 
inhibitor (INSTI) use (20.7% vs 15.7%, p < 0.001). In addition, there was a difference in the use 
of Efavirenz (51.3% vs 54.8%, p = 0.003) and Dolutegravir (43.1% vs 40.8%, p = 0.048). See S3.1 
for a more detailed analysis of ART treatment over time. Patients with srni reported more often 
high alcohol consumption (12.2% vs. 6.9%, p < 0.001) and intake of recreational drugs (42.6% 
vs 31.0%, p < 0.001).  
 
Patients with similar trends of srni over time 
 The top three cluster groups contain 2’224 (80.8%), 343 (12.5%) and 187 (6.8%) 
patients, respectively (Figure 4A). The three cluster groups are characterized by a different 
mean score of srni over time. The largest cluster group, “Cluster 1”, is characterized by a 
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constant low mean score over time, ranging from a score of 0.29 to 0.45, which is lower 
compared to the overall score, which ranges between 0.49 and 0.73. The second largest cluster 
group, “Cluster 2”, is characterized by a decreasing mean score over time. The mean score was 
1.99 in 2013, which is the highest mean score among the three clusters groups, but was 
decreasing to 0.37 in 2017, i.e., lower compared to “Cluster 1”. The smallest cluster group, 
“Cluster 3”, is characterized by a constant high mean score ranging from 1.72 to 2.4. (Figure 4B). 
See Section S2.2 for more information on srni in the cluster groups and Section S2.3, Figures 
S9-S11, for a subanalysis of “Cluster 1”. 
 
Comparison of the three cluster groups 
 There was no significant difference in the age, gender, ethnicity and BMI of patients 
when comparing patients in “Cluster 1” with patients in the other two cluster groups, 
respectively. The transmission group IDU was significantly associated with being in “Cluster 3” 
compared to “Cluster 1” (OR =1.5, p = 0.029), but the effect disappeared in the adjusted model 
(OR = 1.2, p = 0.5). Patients in “Cluster 1” had a significantly higher CD4 nadir as compared to 
patients in “Cluster 2” (p < 0.001, adjusted: p = 0.002), but no significant difference in the CD4 
nadir was observed between patients in “Cluster 1” and patients in “Cluster 3”. There was no 
significant difference in the CD4/CD8 ratio and occurrence of viral blips when comparing the 
three clusters (Section S3.3-S3.4, Figures S18, S19). However, there were significant 
differences in the prevalence of previous opportunistic infections as well as opportunistic 
infections of the CNS, with an odds ratio of 1.8 (p = 0.004; adjusted OR = 1.5, p = 0.06) for 
“Cluster 2” and an odds ratio of 3.4 (p < 0.001; adjusted OR = 3.9, p < 0.001) for “Cluster 3”. No 
significant differences between the prevalence of HCV and syphilis could be seen in both 
comparisons. The difference in the prevalence of depression was significant in the comparison 
of “Cluster 1” with “Cluster 3” with an odds ratio of 3.2 (p < 0.001; adjusted OR = 1.9, p < 0.001), 
but the effect disappeared in the adjusted model for the comparison of “Cluster 1” with “Cluster 
2” (OR = 1.8, p < 0.001; adjusted OR = 1, p =0.9). There was a significant difference between the 
proportion of patients who reported imperfect adherence to ART when comparing “Cluster 1” 
with “Cluster 3” (OR = 2.2, p < 0.001; adjusted OR = 3.1, p < 0.001). No significant difference 
between drug classes were seen, except for the prescription of dolutegravir (Section S3.1-S3.2, 
Figures S12-S17). Patients in “Cluster 3” reported more often high alcohol consumption 
compared to “Cluster 1” (OR = 2.0, p < 0.001; adjusted OR = 1.7, p = 0.009). There was no 
significant difference in recreational drug use when comparing the cluster groups, neither for all 
the single substances analyzed (Section S3.5, Figure S20). 
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Discussion 
 The overall proportion of patients with srni in the SHCS was decreasing over the last 5 
years in all three domains, namely memory loss, slowing down in reasoning and concentration 
problems. This is surprising when comparing our results to other longitudinal studies about 
neurocognitive impairment in resource-rich countries: Sacktor et al (16) found an increase of 
HAND in the years 2009-2012, emphasized however that HAND was not a progressive condition 
for the majority of virally suppressed participants. Similarly, Heaton et al (17) followed patients 
in the CNS HIV Antiretroviral Therapy Effects Research Cohort and found slightly more patients 
with worsening compared to improving neurocognitive impairment. However, our study 
analyzes for the first time longitudinal srni for a very large cohort, including a broad patient 
population not restricted to any patient characteristics such as age or prior knowledge on 
neurocognitive or psychiatric problems.  
Despite the overall decline of srni, there are still patients with persisting srni. It is well-
known that effective ART alone cannot eliminate neurocognitive problems, e.g., Simioni et al 
showed that also patients with long-standing suppression of viremia show cognitive dysfunction 
(10). It is therefore crucial to understand different factors associated with srni and to identify 
groups of patients without improvement over time. 
By using machine learning techniques, we identified groups of patients with similar 
changes of srni over time. We employed a clustering algorithm with parameters tailored to this 
research question to identify patterns in the data set. Using hierarchical clustering algorithms to 
detect patterns in large longitudinal data sets is informative and has been used before for 
epidemiological research in HIV cohorts (18). 
Most patients belonged to “Cluster 1”, characterized by a low mean score of srni. We 
could identify two more cluster groups of patients: “Cluster 2”, characterized by a decreasing 
mean score of srni, has a higher proportion of patients with previous CNS opportunistic 
infections and depression as compared to “Cluster 1”. Patients in “Cluster 3”, characterized by a 
high mean score of srni not improving over time, had as well more often a previous CNS 
opportunistic infections, depression and imperfect adherence to ART as compared to “Cluster 1”. 
It is interesting that although most CNS opportunistic infections happened long ago (Section 
S1.6), this was factor had the largest impact on srni. Noteworthy, imperfect adherence to ART 
was significantly higher in “Cluster 3” compared to “Cluster 1”, but not for “Cluster 2”. In a 
smaller pilot study from the SHCS, Kamal et al (9) showed a correlation between adherence and 
HAND (and other non-psychiatric cognitive impairment), where adherence was measured with a 
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medication electronic monitoring system and all patients had neuropsychological evaluations. 
Moreover, it was shown that self-reported adherence to ART as measured in the SHCS correlates 
well with virologic failure and mortality (13), suggesting that self-reported adherence correlates 
well with actual adherence. Due to small effects, many different drug regimens and changes in 
ART prescriptions, as well as considerable potential for confounding and selection bias, we 
refrained from interpreting weak differences seen in different drugs or drug classes. One factor 
which was significant in both comparisons was depression, which shows the importance of 
taking into consideration psychiatric comorbidities when assessing srni.  
 Studying neurocognitive impairments in a large patient population longitudinally is 
hardly feasible, due to expensive and time-consuming neuropsychological testing to diagnose 
HAND. In accordance with EACS guidelines, the SHCS included three questions about memory 
loss, slowing down in reasoning and concentration problems in the follow-up interview for all 
patients. This allowed us to study srni in a large and representative patient population 
encompassing all major transmission groups. One limitation of this study is that srni might not 
translate into actual neurocognitive impairments. In a large sub study of the SHCS, the NAMACO 
(Neurocognitive Assessment in the Metabolic and Aging Cohort) study, 981 participants 
underwent standardized neuropsychological assessment by neuropsychologists (19,20). The 
overall prevalence of neurocognitive impairment, as diagnosed using Frascati criteria, was 40% 
and 27% of the participants were diagnosed with HAND (19). Simioni et al (10) analyzed the 
correlation of HAND with the three neurocognitive questions in 50 patients with and 50 patients 
without srni, excluding patients with depression. They found a prevalence of HAND in 84% of 
patients with srni (24% asymptomatic HAND for patients with srni), and a prevalence of HAND 
in 64% for patients without srni (60% asymptomatic HAND for patients without srni). Hence, 
this sub study only found a weak association between the three questions on srni and actual 
neurocognitive impairment. In particular, patients with asymptomatic forms of HAND could not 
be detected with these subjective questions. The positive and negative predictive values of the 
three questions to predict cognitive impairment is unknown but will be analyzed within the 
NAMACO study. Our study, however, uses longitudinal information on srni. Having persistent 
srni over a longer period of time might hence be less susceptible to the conditions on that day 
and potentially yield a higher correlation with HAND. Having said that, any associations of the 
three questions and HAND are still uncertain and formal testing for HAND in patients with 
persisting srni would be the next step and planned in the NAMACO study. One limitation 
regarding the analysis of risk factors is that reactive syphilis tests are an imperfect marker for 
syphilis and we cannot distinguish between incident and prevalent syphilis. 
 In summary, our findings show that srni significantly decreased in 2013-2017, which 
most likely can be attributed  to more potent and earlier initiation of therapies used in recent 
years (21,22) and decreasing  treatment failures in the SHCS (23). Furthermore, our results 
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suggest that all patients with a history of CNS opportunistic infections should be screened in-
depth for neurocognitive problems, even if the opportunistic infection occurred a long time ago 
and the patient has been on suppressive ART for many years. In addition, patients reporting 
imperfect adherence to ART or having a depression should be considered for further screening 
of neurocognitive problems. Selecting patients for in-depth neurocognitive screening based on 
these three criteria is in particular useful for cohorts and patients without longitudinal 
information about srni. 
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FIGURES and TABLES 
 
Figure 1 
Flow chart to illustrate the study design. 
 
Figure 2: Schematic representation of the hierarchical cluster algorithm used to find clusters of patients 
with similar scores of self-reported neurocognitive impairments over time. 2A: Trajectories of the score 
(0 to 3) over time. 2B: The area under the curve (AUC) of the trajectories for each year 2013 to 2017. 2C: 
The pairwise distances of the AUCs of the patients. 2D: The resulting dendrogram of the patients. 
 
Figure 3: The percentage of patients with self-reported neurocognitive impairment from 2013 until 2017. 
‘Questionnaires’ denotes the number of completed questionnaires on the three questions about 
neurocognitive impairment and ‘Patients’ the respective number of patients. 
 
Figure 4: 4A) The dendrogram resulting from the cluster algorithm. We chose to pick the top three 
cluster groups for further analysis. 4B) The mean scores in the three top cluster groups, in addition to the 
overall mean score of all patients included in the cluster analysis. See Section S2.1, Figures S6-S8, for 
further sub cluster groups. 
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Table 1 
Variable   Patients with self-reported 
neurocognitive impairment 
Patients without self-reported 
neurocognitive impairment 
p value 
Self-reported neurocognitive 
impairment 
Any domain 2'754 5'791   
  Concentration (n, perc) 1'724 (62.6%)     
  Slowing down in reasoning (n, perc) 1'291 (46.9%)     
  Memory loss (n, perc) 2'366 (85.9%)     
Years of follow-up (median, IQR) 4.2 [3.9, 4.5] 4.3 [4.0, 4.5] 0.029 
Completed questionnaires (median, IQR) 9.0 [8.0, 9.0] 9.0 [8.0, 9.0] 0.108 
Birth year (median, IQR) 1965 [1959, 1971] 1966 [1960, 1974] < 0.001 
Diagnosis year (median, IQR) 2001 [1993, 2007] 2003 [1996, 2008] < 0.001 
Sex male (n, perc) 1'910 (69.4%) 4'206 (72.6%) 0.002 
Ethnicity white (n, perc) 2'177 (79.0%) 4'542 (78.4%) 0.535 
Risk group Intravenous drug users (n, perc) 481 (17.5%) 511 (8.8%) < 0.001 
  Men who have sex with men (n, perc) 1'102 (40.0%) 2'754 (47.6%) < 0.001 
  Heterosexual (n, perc) 1'025 (37.2%) 2'255 (38.9%) 0.128 
  Other (n, perc) 146 (5.3%) 271 (4.7%) 0.217 
Highest body mass index (median, IQR) 26.1 [23.7, 29.2] 25.9 [23.5, 28.7] 0.021 
CD4 nadir (median, IQR) 190 [84, 288] 209 [101, 312] < 0.001 
Lowest CD4/CD8 ratio (median, IQR)  0.22 [0.12, 0.36] 0.24 [0.14, 0.39] < 0.001 
Viral load AUC: 2013-2017, copies/mL (median, IQR) 910.0 [0.0, 14511.0] 0.0 [0.0, 12816.7] 0.083 
  Viral blips (n, perc) 979 (35.5%) 1'837 (31.7%) < 0.001 
Opportunistic infections Any (n, perc) 1'385 (50.3%) 2'496 (43.1%) < 0.001 
  Central nervous system (n, perc) 168 (6.1%) 190 (3.3%) < 0.001 
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Hepatitis C   (n, perc) 664/2'742 (24.2%) 880/5'751 (15.3%) < 0.001 
Syphilis any positive test (n, perc) 686 (24.9%) 1'557/5'787 (26.9%) 0.052 
  first test positive (n, perc) 324 (11.8%) 663/5'787 (11.5%) 0.690 
Depression (n, perc) 1'261 (45.8%) 1'312 (22.7%) < 0.001 
Antiretroviral therapy On ART (n, perc) 2'738 (99.4%) 5'750 (99.3%) 0.571 
 Years on ART (median, IQR) 14.1 [8.4, 20.4] 12.0 [7.1, 19.2] < 0.001 
 Imperfect adherence (n, perc) 431/2'739 (15.7%) 548/5'746 (9.5%) < 0.001 
 NNRTI (n, perc) 1'778 (64.6%) 3'868 (66.8%) 0.042 
 PI (n, perc) 2'153 (78.2%) 3'978 (68.7%) < 0.001 
 INSTI (n, perc) 570 (20.7%) 909 (15.7%) < 0.001 
 Efavirenz (n, perc) 1'413 (51.3%) 3'173 (54.8%) 0.003 
 Dolutegravir (n, perc) 1'186 (43.1%) 2'362 (40.8%) 0.048 
High alcohol consumption (n, perc) 337 (12.2%) 400 (6.9%) < 0.001 
Recreational drugs Any drug (n, perc) 1'166/2'736 (42.6%) 1'779/5'739 (31.0%) < 0.001 
  Cannabis (n, perc) 1'000/2'736 (36.5%) 1'504/5'739 (26.2%) < 0.001 
  Cocaine (n, perc) 513/2'736 (18.8%) 778/5'739 (13.6%) < 0.001 
  MDMA/XTC (n, perc) 222/2'736 (8.1%) 397/5'739 (6.9%) 0.050 
  Heroin (n, perc) 224/2'736 (8.2%) 169/5'739 (2.9%) < 0.001 
  Chemsex drugs (n, perc) 160/2'736 (5.8%) 262/5'739 (4.6%) 0.012 
  LSD (n, perc) 33/2'736 (1.2%) 31/5'739 (0.5%) 0.002 
Table 1: Basic characteristics of the study population. In case not all patients had information about the corresponding variable, we reported the number at risk in addition 
(e.g. for Hepatitis C). IQR = interquartile range, Syphilis ‘ever’ refers to least one positive syphilis test recorded in the SHCS, Syphilis ‘previous’ refers to patients whose first 
syphilis test was positive, ART = antiretroviral therapy, NNRTI = non-nucleoside reverse transcriptase inhibitor, PI = protease inhibitor, INSTI = integrase inhibitor, 
MDMA/XCT = 3,4-Methylendioxy-N-methylamphetamin, Chemsex drugs = Methamphetamine, GHB (4-hydroxybutyric acid), Mephedrone or Ketamine, LSD (Lysergic acid 
diethylamide
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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